Canbiola is Registered and Active in the GSA's System for Award Management (SAM) and Department of Defense (DOD)

HICKSVILLE, NY, March 14, 2019 -- InvestorsHub NewsWire -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today that it is now registered and active in the U.S. government GSA’s System for Award Management (SAM) and Department of Defense (DOD).

System for Award Management. SAM is streamlining processes, improving data quality by eliminating the need to enter the same data multiple times, and consolidating hosting to save taxpayer money. The System for Award Management (SAM) is an official website of the U.S. government. There is no cost to use SAM. GSA’s Office of Government-wide Policy is consolidating federal procurement and award systems into 1 new system—the System for Award Management (SAM). SAM is streamlining processes, improving data quality by eliminating the need to enter the same data multiple times, and consolidating hosting to save taxpayer money.

The registration number for Canbiola, Inc. is 789110553 / 5C7D3 and is now active in the U.S. federal government's System for Award Management (SAM/DOD).

For additional information, please visit:

https://www.sam.gov/SAM/

https://www.acq.osd.mil/dpap/pdi/eb/system_for_award_management.html

Canbiola Chief Executive Officer Marco Alfonsi, commented, "Attaining SAM and DOD registration is quite an accomplishment and something our team at Canbiola had been working on for some time. We are proud to now be active in the system, which enables our products to be more widely available to those who seek CBD solutions. We look forward to being an active participant in the U.S. government program. Canbiola Chief Executive Officer Marco Alfonsi, commented, “Attaining SAM and DOD registration is quite an accomplishment and something our team at Canbiola had been working on for some time. We are proud to now be active in the system, which enables our products to be more widely available to those who seek CBD solutions. We look forward to being an active participant in the U.S. government program.”

About Canbiola, Inc.

Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews,, isolate, gel caps, and concentrates. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. Hemp CBD is the non-psychoactive component (No THC) used for treatment of pain, inflammation, and wellness programs.  For more information about Canbiola, Inc., please visit: https://canbiola.com.

Additionally, Canbiola’s wholly owned subsidiary Pure Health Products, based in Lacey, WA, is its prime development laboratory and production facility.  Canbiola’s Duramed division has recently rolled out a durable medical device via its Doctor network to treat patients with injuries via application of an in-home ultrasound sustained acoustic device for pain and inflammation reduction.

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Follow Canbiola on: 

Twitter @CanbiolaHealth

Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd

Follow us on Twitter and Facebook

Investors and Media:

[e-mail]
[phone]
Hayden IR
[e-mail]
[phone]